retatrutide type 2 diabetes phase 2 weight loss for Triple hormone receptor agonist metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial Retatrutide is gaining attention in – Reta and Type 2 Diabetes

Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials

In people whose vagus nerve was surgically cut (below the diaphragm, not in the neck), GLP-1 did not reduce food intake or accelerate metabolism

10.1038/s41580-020-00324-8 Nat Rev Mol Cell Biol

A protein encoded by the locus tag Amuc_1409 was purified with an N-terminal His-tag from overproducing E.coli and was found to stimulate growth and increase the number of lobes in murine as well as human intestinal organoids

Patients need to discuss potential side effects with their healthcare provider to ensure safe and effective use of GLP-1 receptor agonists.